BC Extra | Mar 11, 2019
Clinical News

Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...
BC Week In Review | Dec 21, 2018
Company News

Axovant gets rights to gene therapies from UMass medical school

The University of Massachusetts Medical School (Worcester, Mass.) granted Axovant exclusive, worldwide rights to develop and commercialize two gene therapies to treat GM1 and GM2 gangliosidoses. The school received $10 million up front and is...
Items per page:
1 - 2 of 2